Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.3620
-0.0060 (-1.63%)
At close: Jan 9, 2026, 4:00 PM EST
0.3623
+0.0003 (0.08%)
After-hours: Jan 9, 2026, 7:04 PM EST
Virax Biolabs Group Market Cap
Virax Biolabs Group has a market cap or net worth of $2.69 million as of January 9, 2026. Its market cap has decreased by -67.77% in one year.
Market Cap
2.69M
Enterprise Value
-212.57K
1-Year Change
-67.77%
Ranking
Category
Stock Price
$0.36
Market Cap Chart
Since the IPO on July 21, 2022, Virax Biolabs Group's market cap has decreased from $207.01M to $2.69M, a decrease of -98.70%. That is a compound annual growth rate of -71.36%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 9, 2026 | 2.69M | 4.68% |
| Dec 31, 2025 | 2.57M | -73.72% |
| Dec 31, 2024 | 9.77M | 269.37% |
| Dec 29, 2023 | 2.64M | -71.76% |
| Dec 30, 2022 | 9.36M | -95.48% |
| Jul 21, 2022 | 207.01M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 965.86B |
| Johnson & Johnson | 495.11B |
| AbbVie | 392.44B |
| UnitedHealth Group | 312.00B |
| AstraZeneca | 295.31B |
| Merck & Co. | 276.47B |
| Novartis AG | 273.11B |
| Novo Nordisk | 256.73B |